The estimated Net Worth of Dov Elefant is at least $337 Тысяча dollars as of 28 December 2020. Mr. Elefant owns over 7,407 units of Cellectar Biosciences Inc stock worth over $24,568 and over the last 9 years he sold CLRB stock worth over $0. In addition, he makes $312,437 as Chief Financial Officer и Vice President at Cellectar Biosciences Inc.
Dov has made over 2 trades of the Cellectar Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 7,407 units of CLRB stock worth $9,999 on 28 December 2020.
The largest trade he's ever made was buying 7,407 units of Cellectar Biosciences Inc stock on 28 December 2020 worth over $9,999. On average, Dov trades about 1,679 units every 29 days since 2015. As of 28 December 2020 he still owns at least 11,755 units of Cellectar Biosciences Inc stock.
You can see the complete history of Mr. Elefant stock trades at the bottom of the page.
Dov Elefant serves as Chief Financial Officer, Vice President of the Company. Mr. Elefant was appointed our Vice President and Chief Financial Officer in September 2019. Mr. Elefant has more than 20 years of industry experience at both public and private biopharmaceutical companies. Most recently, he served as Chief Financial Officer of Akari Therapeutics PLC, a publicly-traded biopharmaceutical company specializing in treatments for autoimmune and inflammatory diseases, from September 2015 to August 2019. Prior to his service at Akari Therapeutics, PLC, Mr. Elefant served as Chief Financial Officer of Celsus Therapeutics, Inc., a publicly-traded biopharmaceutical company, from January 2012 to September 2015. Mr. Elefant holds a B.S. in accounting from Yeshiva University.
As the Chief Financial Officer и Vice President of Cellectar Biosciences Inc, the total compensation of Dov Elefant at Cellectar Biosciences Inc is $312,437. There are 5 executives at Cellectar Biosciences Inc getting paid more, with James Caruso having the highest compensation of $934,460.
Dov Elefant is 52, he's been the Chief Financial Officer и Vice President of Cellectar Biosciences Inc since 2019. There are 7 older and 4 younger executives at Cellectar Biosciences Inc. The oldest executive at Cellectar Biosciences Inc is Frederick Driscoll, 69, who is the Independent Director.
Dov's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC.,, 100 CAMPUS DRIVE, FLORHAM, NJ, 07932.
Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over $1,263,511 worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth $3,966,598 . The most active insiders traders include Austin W & Greenhouse David..., Investment Company, Inc. Awm и John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of $126,821. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth $26,000.
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
Cellectar Biosciences Inc executives and other stock owners filed with the SEC include: